| UHC UMR Medical and Drug | Oxlumo® (Lumasiran) and Rivfloza® (Nedosiran) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Skyrizi® (Risankizumab-Rzaa) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Tremfya® (Guselkumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | White Blood Cell Colony Stimulating Factors – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Xolair® (Omalizumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Surest Medical and Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Surest Medical and Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Surest Medical and Drug | Lemtrada® (Alemtuzumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Surest Medical and Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC Surest Medical and Drug | Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs – Commercial Medical Benefit Drug Policy | 2025-10-01 |